Gleptoferron Labiana 200 mg/ml Solution for Injection

国: アイルランド

言語: 英語

ソース: HPRA (Health Products Regulatory Authority)

有効成分:

Gleptoferron

から入手可能:

Labiana Life Sciences, S.A.

ATCコード:

QB03AC91

INN（国際名）:

Gleptoferron

投薬量:

200 milligram(s)/millilitre

医薬品形態:

Solution for injection

処方タイプ:

LR: Licensed Retailer as defined in national legislation

治療群:

Pigs

治療領域:

ZZZ Gleptoferron

適応症:

Vitamins and minerals

認証ステータス:

Authorised

承認日:

2016-12-23

製品の特徴

Health Products Regulatory Authority
21 January 2022
CRN00CH24
Page 1 of 4
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Gleptoferron Labiana 200 mg/ml Solution for Injection
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
​
Each ml contains:
​
​
​
Active substance:
​
​
​
Iron (III)
200.00
mg​
(as Gleptoferron 532.6 mg)​
​
​
​
Excipients:
​
​
​
Phenol
​
5.0
​mg
​
For the full list of excipients, see section 6.1
​
​
3 PHARMACEUTICAL FORM
Solution for injection.
A dark brown, slightly viscous, sterile, colloidal, aqueous solution
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Neonatal pigs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the prevention and treatment of iron deficiency anaemia.
4.3 CONTRAINDICATIONS
Do not use in case of:
- Hypersensitivity to gleptoferron complex or any of the excipients.
- In animals with hepatic and/or renal disease.
- Do not administer to piglets suspected to suffer from deficiency of
vitamin E and/or selenium.
- Do not use in clinically diseased animals, especially not in case of
diarrhoea.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
The sachet in the low-density polyethylene collapsible bottles with a
nominal capacity of 100 ml and 200 ml should not be
opened until the product is required for use.
Health Products Regulatory Authority
21 January 2022
CRN00CH24
Page 2 of 4
4.5 SPECIAL PRECAUTIONS FOR USE
i) Special precautions for use in animals
Normal aseptic injection techniques should be practised.
Avoid the introduction of contamination during use.
It is advisable to stretch the skin at the injection site to minimize
leakage after withdrawal of the needle.
ii) Special precautions to be taken by the person administering the
veterinary medicinal product to animals
People with known hypersensitivity to the active substance
(gleptoferron) or with hemochromatosis should avoid contact with
the veterinary medicinal product.
Take care to avoid accidental self-injection as well as contact with
the eyes, mouth a